Induction of remission in autoimmune polyglandular syndrome type three (APS III): An old drug with new perspectives

被引：6

作者：

Allam, Magdy Mohamed ^{[1
]}

Elzawawy, Hanaa Tarek Hussein ^{[2
]}

机构：

[1] AUSH, Dept Internal Med, Alexandria, Egypt

[2] Alexandria Univ, Dept Internal Med, Fac Med, Alexandria, Egypt

来源：

CLINICAL CASE REPORTS | 2018年 / 6卷 / 11期

关键词：

autoimmune polyglandular syndrome; autoimmune polyglandular syndrome type III; azathioprine; Grave's disease; Hashimoto's thyroiditis; hyperthyroidism; hypothyroidism; type 1 diabetes mellitus; vitiligo;

D O I：

10.1002/ccr3.1827

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The autoimmune polyglandular syndrome is a sequential chain of autoimmune events. Whenever diagnosed, the clinician's target should be induction of remission and if possible hindering its progression especially if associated with refractory vitiligo, resistant Grave's, or unexplained hyperglycemia in T1DM. Azathioprine could be used for induction of remission in autoimmune polyglandular syndrome type three especially with vitiligo and autoimmune thyroiditis.

引用

页码：2178 / 2184

页数：7

共 21 条

[1] 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum [J].